PET imaging for GPC3 in liver cancer
Part of Cancer, Digestive system clinical trials.
This study tests a new PET imaging method that targets GPC3, a protein often found in liver cancer cells. It may help doctors see and understand liver cancer better, especially in people with newly diagnosed or recurrent disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have been diagnosed with or are strongly suspected of having hepatocellular carcinoma (a type of liver cancer)
- You are willing to have a biopsy or a standard FDG-PET scan as part of the study
- You are not pregnant or nursing
- You have no known allergies to the GPC3 imaging agent used in this study
- Your fasting blood sugar is below 11.0 mmol/L (about 198 mg/dL) before the FDG-PET scan
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial uses a special PET scan that targets a protein found in liver cancer cells. It aims to see if this new scan works better than an enhanced MRI to find liver cancer. If you have suspected or confirmed liver cancer, this study might help guide your care.
This trial uses a special SPECT scan that targets GPC3, a protein found on some liver cancer cells, to see if it can help detect or monitor hepatocellular carcinoma (HCC). It may be an option for people suspected of having HCC, diagnosed with it, or experiencing a recurrence after treatment.
This trial is testing a new imaging method using a special tracer (GPA33) to find tumors in people with colorectal, gastric, or pancreatic cancer. It may help doctors see tumors more clearly during a PET scan.
This study tests a new PET/CT imaging agent (gallium-68 FFD) to see how well it works in both healthy volunteers and people with solid tumors. It could help doctors find or monitor cancer more accurately.
This study tests a new PET imaging agent called [68Ga]Ga-ELI411 to help see tumors more clearly. It is for adults with solid tumors who are already scheduled for a standard PET scan, and may help doctors better understand and manage their cancer.
This study uses a special PET/CT scan that targets a protein (GPC3) found in liver cancer cells. The goal is to see how well it can detect or track liver cancer, whether it's newly diagnosed or has been treated before.
Hear when a new Malignant Neoplasm of Liver trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.